**Brief Communication**

**Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine**

Jonah J. Scott-McKean¹ and Alberto C.S. Costa¹,²,³,⁴

¹Neuroscience Training Program, University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA; ²Division of Clinical Pharmacology and Toxicology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA; ³Colorado Intellectual and Developmental Disability Research Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA

The Ts65Dn mouse is the best-studied animal model for Down syndrome. In the experiments described here, NMDA-mediated or mGluR-mediated LTD was induced in the CA1 region of hippocampal slices from Ts65Dn and euploid control mice by bath application of 20 μM NMDA for 3 min and 50 μM DHPG for 5 min, respectively. We found that Ts65Dn mice display exaggerated NMDA-induced, but not mGluR-induced, LTD in the CA1 region of the hippocampus compared with euploid control animals. In addition, this abnormal level of LTD can be pharmacologically rescued by the NMDA receptor antagonist memantine.

Our research team has found previously that the Ts65Dn mouse displays pharmacological responses consistent with dysfunction in molecular pathways coupled to the gating of NMDARs (Costa et al. 2008; Siddiqui et al. 2008). Proteins encoded by nine genes located on chromosome 21 and in the Ts65Dn trisomic segment (APP, TIAM1, BACH1, SOD1, SYNJ1, ITSN1, RCAN1, DYRK1A, and PCP4) have been shown to interact either directly with NMDARs, or indirectly via the protein phosphatase calcineurin (CaN) (Siddiqui et al. 2008; Gardiner 2010). Inhibition of CaN activity alters NMDAR gating kinetics (Lieberman and Mody 1994) and causes increased sensitivity to the stimulatory locomotor actions of the NMDAR antagonist MK-801 (Miyakawa et al. 2003). The Ts65Dn and Ts1Cje mouse models of DS display similar hypersensitivity to these psychotomimetic actions of MK-801 (Costa et al. 2008; Siddiqui et al. 2008), which supports the hypothesis that CaN is inhibited in these animal models and that, consequently, NMDAR function may indeed be altered. In addition, we also have found that acute doses of the low-affinity uncompetitive NMDAR antagonist memantine rescue learning and memory deficits in Ts65Dn mice in a fear-conditioning test (Costa et al. 2008). More recently, two separate research groups have confirmed memantine's memory/learning enhancing effects on Ts65Dn mice (Lockrow et al. 2010; Rueda et al. 2010). Therefore, we have hypothesized that, differently from the FMR1 null mutant mouse, an NMDAR-dependent mechanism might underlie the exaggerated LTD seen in Ts65Dn mice. Moreover, we have hypothesized that the drug memantine might be able to rescue this altered level of synaptic plasticity in these animals.

The original production of the segmental trisomy Ts65Dn has been well described in the literature (Reeves et al. 1995; Costa et al. 1999). Experimental mice used here were generated by repeated back-crossing of Ts65Dn females to C57BL/6Jei × C3Sn.BLIA-Pde6b + / D F1 hybrid males (as described by Costa et al. 2010) in colonies at the University of Colorado Anschutz Medical Campus or The Jackson Laboratory. The euploid litters of Ts65Dn mice were used as controls. Animals from the...
same litter and sex were housed in the same cage and maintained in a 12:12 h light/dark schedule (lights on at 7:00 am) with free access to food and water. Only males (aged 6–8 mo) were used in this study. The experimental methods have received approval of the University of Colorado Anschutz Medical Campus Animal Care and Use Committee.

Adult Ts65Dn and euploid littermate control mice aged 6–8 mo were used in this experiment. Mice were decapitated under halothane anesthesia, and the brains were rapidly harvested in ice-cold dissecting artificial cerebral spinal fluid (aCSF) (in mM: 210 Sucrose, 2.5 KCl, 1 CaCl₂, 7 MgSO₄, 1.5 NaH₂PO₄, 26 NaHCO₃, and 10 D-glucose, saturated with 95% O₂ and 5% CO₂) and cut with a vibrating blade microtome (VT 1000s, Leica) into transverse slices 400-μm thick. The hippocampus was then dissected out and the CA3 region was removed. Slices were moved to a holding chamber containing aCSF (in mM: 120 NaCl, 3.5 KCl, 2.5 CaCl₂, 1.3 MgSO₄, 1.25 NaH₂PO₄, 26 NaHCO₃, and 10 D-glucose, saturated with 95% O₂ and 5% CO₂) and allowed to recover for at least 1 h at room temperature. Half of the slices were then moved to another holding chamber with aCSF containing 1 μM memantine. Both sets of hippocampal slices were allowed to recover for an additional 4 h before being placed in the recording chamber. The concentration of memantine used in this study was derived from published data indicating that at steady-state (chronic treatment for several weeks) and therapeutic doses (typically 20–30 mg/day), plasma levels of memantine are in a range of from 0.4 to 1 μM (Kornhuber and Quack 1995; Danyss et al. 1997; Periclou et al. 2006). Also, at the concentration of 1 μM memantine, Chen and Lipton (1997) demonstrated ~50% inhibition of NMDA-gated whole-cell currents recorded from retinal ganglion cells, voltage clamped at −60 mV, and elicited by a saturating (200 μM) concentration step of NMDA applied through a fast superfusion system (flow pipes). Thus, at 1 μM memantine, it is unlikely that the occupancy of NMDARs will be close to saturation levels.

In the present study, a customized electrophysiology setup was designed to allow for simultaneous recordings of treated (memantine) and untreated hippocampal slices from the same animal. In all experiments, we used only one hippocampal slice per animal per condition and, consistently, n = 12. Field excitatory postsynaptic potentials (fEPSP) were recorded with nichrome recording electrodes through thin-walled borosilicate glass micropipettes (3–5 MΩ resistance, 1.5 mm, WPI) filled with aCSF. The pipette was inserted in to the apical dendritic layer of the CA1 region of the hippocampus. Two fine bipolar PI/Ir electrodes (FHC) were inserted in the CA1 stratum radiatum on opposite sides of the recording pipette (electrodes were designated S1 and S2). These electrodes provided alternative ways of stimulating the Schaffer collateral pathway and testing the consistency of the fEPSP recordings (the data shown here were produced via stimulation of the S1 electrode; see Supplemental data for S2-generated recordings). A stable baseline of synaptic transmission was established for 20 min prior to induction of LTD. Stimulation intensity was adjusted to 40%–50% of the amplitude required to producing population spikes. Signals from the recording electrode were amplified 2000–5000 times (Brownlee Precision Electrophysiology Amplifier with signal conditioner, Model 440), low-pass filtered at 2 kHz, and digitized by a Digidata digitizer (1322A, Axon Instruments) into a PC microcomputer. PCLAMP software (Version 8.1, Axon Instruments) was used for data acquisition, and analysis was performed off-line. After establishing a stable baseline, either 20 μM NMDA was bath applied for 3 min to induce NMDA-mediated LTD, or

---

**Figure 1.** LTD induced by bath application of either NMDA (5 μM, 3 min) or DHPG (20 μM, 5 min). (A,D) Normalized fEPSP slopes before and after bath application of NMDA. Notice that the hippocampal slices from Ts65Dn mice displayed larger levels of NMDA-induced LTD than those from the euploid control animals, and that preincubation with memantine (1 μM, 4 h) rescued this phenotype. (C,D) Normalized fEPSP slopes before and after bath application of DHPG. Here, the levels of LTD in Ts65Dn mice and euploid control animals are indistinguishable with or without preincubation with memantine. (In A–D, calibration bars represent 1 mV and 10 msec.) (E) Summary graph representation of the ANOVA of the LTD data (mean fEPSP depression ± SEM; with fEPSP depression = the average baseline fEPSP slope—average fEPSP slope during the last 10 min of recording for each hippocampus slice) in A and C showing which differences reached significance in the post hoc analyses. (F) Summary graph representation of the ANOVA of the LTD data (mean ± SEM) in B and D. Statistical significance is expressed in this figure: (**) P < 0.01.
50 μM group 1 mGluR agonist [3,5-RS] dihydroxyphenylhydrazine (DHPG) was bath applied for 5 min to induce mGluR-mediated LTD, and fEPSP's were recorded for an additional 60 min. Data for time points 0–14 min in Figure 1 (and Supplemental Fig. 1) have been omitted to help make the graphs easier to read. Analysis of time points for 0–3 min for NMDA-mediated LTD, and 0–5 min for mGluR-mediated LTD did not indicate significant differences in the dynamic parameters of LTD induction between control and Ts65Dn mice (supplemental Tables 1 and 2).

Figure 1A depicts LTD produced by a 3-min bath application of 20 μM NMDA on the hippocampal slices. The resulting data showed that slices from Ts65Dn mice displayed an exaggerated LTD compared with euploid control animals. In contrast, we found that a 5-min bath application of the 50 μM group 1 mGluR agonist DHPG produced indistinguishable levels of LTD in slices of Ts65Dn and control mice (Fig. 1B). Interestingly, additional experiments showed that the exaggerated level of NMDA-induced LTD could be rescued pharmacologically by preincubation of the slices in 1 μM memantine (Fig. 1C). However, preincubation with memantine at this same concentration did not produce any significant change in the level of DHPG-induced LTD in slices from either Ts65Dn or littermate control mice (Fig. 1D).

The bar graphs in Figure 1E summarize Analysis of Variance (ANOVA) results for the mean levels of NMDA-induced LTD (expressed as the mean percentage of the baseline level ± SEM) in four groups of hippocampal slices shown in Figure 1A and C: (1) untreated control; (2) untreated Ts65Dn; (3) control preincubated with memantine; and (4) Ts65Dn preincubated with memantine. We found a significant group effect (F(3, 44) = 4.077, P = 0.0122), and Fisher’s PLSD post hoc comparisons revealed a significant difference between untreated control and untreated Ts65Dn slices without memantine (P = 0.0027), but no significant difference between untreated control slices and Ts65Dn slices preincubated in memantine (P = 0.7422). Figure 1F will summarize the ANOVA of DHPG-induced LTD data (i.e., the results shown in Fig. 1B,D). As can be inferred from the inspection of the figures, we found no significant group effect (F(3, 44) = 0.827, P = 0.4862) in these experiments.

In order to investigate other potential effects of memantine on basic synaptic function of Ts65Dn and euploid control mice, we performed assessments of input/output (I/O) relationships and paired-pulse facilitation (PPF) for the four groups of hippocampal slices, i.e., untreated control, untreated Ts65Dn, control preincubated with memantine, and Ts65Dn preincubated with memantine (n = 12 for each group). Analysis of the I/O function plot by repeated measures ANOVA showed no significant group differences (F(3, 44) = 0.8243; P = 0.7115) (Fig. 2A), nor did it indicate interaction between group and stimulus intensity (F(27, 396) = 0.5447; P = 0.9709). However, as expected, there was a significant stimulus intensity effect (F(9, 396) = 139.09; P < 0.001). We also investigated PPF, which is a form of short-lived plasticity sensitive to presynaptic changes. In a subset of slices, PPF was produced by delivering two stimuli of identical strength at different interpulse intervals to assess the integrity of presynaptic mechanisms in Ts65Dn mice. PPF was calculated as the slope ratio between the second and first stimuli. Analysis of the data showed no significant group effect (F(3, 44) = 0.431; P = 0.7315) (Fig. 2B) or interaction between genotype and interpulse interval (F(10, 440) = 0.747; P = 0.8335) in the range tested. A strongly significant interpulse interval effect was found (F(10, 440) = 138.011; P < 0.001).

The finding of an exaggerated NMDA-mediated LTD (but not mGluR-mediated LTD) in the CA1 region of the hippocampus of the mouse model of DS Ts65Dn may have interesting consequences in terms of shaping the way we think of the pathophysiology of genetic disorders leading to intellectual disability. As illustrated in Figure 3, one can picture a scenario in which two different genetic insults can lead to essentially the same phenotypic outcome, i.e., exaggerated LTD (likely due to increased internalization of AMPA receptors). However, this common outcome may be reached through very different mechanisms in DS vs. FXS. For DS, it would be the consequence of dysfunction in molecular pathways associated with the induction of NMDA-dependent LTD and, for FXS, it is the result of altered mGluR-dependent protein synthesis.

Post-translational modification of AMPAR leading to decreases in open channel probability and increased AMPAR internalization in response to LTD-inducing stimuli have firmly been implicated in NMDA-dependent LTD for more than a decade (for classic reviews, see Malinow and Malenka 2002; Malenka and Bear 2004). Although there are clear examples of LTP and LTD of NMDAR-mediated currents in the literature (Selig et al. 1995; Montgomery et al. 2005; Morishita et al. 2005), it is unlikely that changes in the NMDAR component of fEPSPs could account for the altered levels of LTD in the Ts65Dn mice described here. This is simply due to the fact that the non-NMDA current component is responsible for the vast majority of fEPSPs under typical electrical stimulation frequencies and intensities and physiological concentrations of Mg2+. (Nishikawa and Maclver 2000). Obviously, further studies specifically designed to quantify receptor post-translational modification and internalization will be needed to test whether altered NMDAR activity-mediated internalization of AMPA receptors in Ts65Dn mice is indeed responsible for the augmented levels of LTD seen in these mice in the present study.

The overarching hypothesis behind the present work is that the exaggerated NMDAR-dependent LTD observed in hippocampal slices from Ts65Dn mice is likely to be the result of direct and indirect interactions of key proteins encoded by trisomic
Fernandez et al. (2007) have provided evidence of increased mice compared with euploid control mice. Finally, studies significant differences in either NR2A or NR2B levels in Ts65Dn comprehensive study by Fernandez et al. (2009), reported no kinesin motor protein, KIF17, compared with euploid control on their observation of a significant decrease in the levels of the impaired trafficking of the NR2B subunit in Ts65Dn mice based in addition, Roberson et al. (2008) proposed a potential role for ebellum of the TgDyrk1A mouse model of DS (Altafaj et al. 2008). This is the recently reported increased NR2A expression in the cerebellum of the TgDyrk1A mouse model of DS (Altafaj et al. 2008). In addition, Roberson et al. (2008) proposed a potential role for impaired trafficking of the NR2B subunit in Ts65Dn mice based on their observation of a significant decrease in the levels of the kinesin motor protein, KIF17, compared with euploid control mice. However, these authors, as well as a more recent and more comprehensive study by Fernandez et al. (2009), reported no significant differences in either NR2A or NR2B levels in Ts65Dn mice compared with euploid control mice. Finally, studies by Kleschevnikov et al. (2004), Costa and Grybko (2005), and Fernandez et al. (2007) have provided evidence of increased γ-aminobutyric acid (GABA) receptor A (GABAAR)-mediated inhibition and/or altered plasticity of the inhibitory circuitry in Ts65Dn mice compared with euploid control animals. Under these circumstances, one could hypothesize that such enhanced GABAAR-mediated synaptic activity might shift neuroplasticity thresholds in favor of LTD at the expense of LTP in Ts65Dn mice. However, such a hypothesis is in direct contradiction with the experimentally observed finding here that the increased levels of LTD in Ts65Dn mice can be rescued pharmacologically by the NMDAR antagonist memantine. In the present work, we propose that the pharmacological rescue of the exaggerated level of LTD in Ts65Dn mice by memantine, which has no effect on the level of DHPG-induced LTD, provides a potential mechanism by which memantine exerts its memory/learning enhancing actions in Ts65Dn mice. Furthermore, these data have their own consequences in terms of rationales for potential pharmacotherapeutic interventions in DS vis-à-vis FXS. For example, these findings provide additional support to the idea that memantine may have disorder-specific therapeutic value on enhancing the cognitive abilities of persons with DS (which we are exploring currently through a single-site investigator-initiated pilot clinical trial; NCT01112683 at http://www.clinicaltrials.gov). In contrast, findings from a small clinical trial in FXS with the Novartis mGluR5 antagonist, AFQ056, have been published (Jacquetmont et al. 2011). Although no significant effects of treatment on the primary outcome measure were found, post hoc analysis of the data showed that a subgroup of seven of the patients with full FMR1 promoter methylation and no detectable FMR1 mRNA in blood cells showed statistically significant improvement in several measures after AFQ056 treatment when compared with placebo.

One should notice that the underlying biology of either DS or FXS is very complex. For example, it is estimated that up to 4% of brain mRNAs may bind FMRP (Brown et al. 2001), whereas trisomy 21 results in the overexpression of 1% of the genes in the entire genome (Sturgeon and Gardiner 2011). Therefore, the same way that the “mGluR hypothesis of FXS” is likely to only account for a portion of the neurodevelopmental phenotype associated with FXS, NMDAR-dependent mechanisms are sure to represent only one of many important factors underlying the neurodevelopmental and neurodegenerative aspects of DS.

Figure 3. Flowchart describing how different genetic insults (trisomy 21 or FMR1 gene mutation) can produce functionally similar phenotypes (exaggerated LTD) through unrelated, parallel mechanisms.

chromosome 21 homologous genes with NMDAR, leading to increased channel opening probability. An alternative, but not mutually exclusive hypothesis would involve altered NMDAR subunit composition in Ts65Dn mice. In support of this hypothesis, increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol Dis 32: 377–384.

Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370–377.

Brown V, Jin P, Ceman S, Darrell JC, O’Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, et al. 2001. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107: 477–487.

Canfield MA, Honen MA, Yusikiv N, Xing J, Mai CT, Collins JS, Devine O, Pettrini J, Ramadhan TA, Hollis CA, et al. 2006. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999–2001. Birth Defects Res A Clin Mol Teratol 76: 747–756.

Chen HS, Lipton SA. 1997. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism. J Physiol 499: 27–46.

Costa AC. 2011. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci. doi: 10.1159/00030861.

Costa AC, Grybko MJ. 2005. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: A model of Down syndrome. Neurosci Lett 382: 317–322.

Costa AC, Walsh K, Davison MT. 1999. Motor dysfunction in a mouse model for Down syndrome. Physiol Behav 68: 211–220.

Costa AC, Scott-McKean JJ, Stasko MR. 2008. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33: 1624–1632.

Costa AC, Stasko MR, Schmidt C, Davison MT. 2010. Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behav Brain Res 206: 52–62.

Danyusz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. 1997. Amino acid antagonism of NMDA receptor antagonists and antiparkinsonian agents–preclinical studies. Neurosci Biobehav Rev 21: 455–468.

Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malekna RC, Garner CC. 2007. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 10: 411–413.
Exaggerated NMDA-LTD in Ts65Dn mouse exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci 100: 8987–8992.

Montgomery JM, Selcher JC, Hanson JE, Madison DV. 2005. Dynamin-dependent NMDAR endocytosis during LTD and its dependence on synaptic state. BMC Neurosci 6: 48. doi: 10.1186/1471-2202-6-48.

Morishita W, Marie H, Malenka RC. 2005. Distinct triggering and expression mechanisms underlie LTD of AMPA and NMDA synaptic responses. Nat Neurosci 8: 1043–1050.

Nishikawa K, Maclver MB. 2000. Excitatory synaptic transmission mediated by NMDA receptors is more sensitive to isoflurane than are non-NMDA receptor-mediated responses. Anesthesiology 92: 228–236.

Patterson D, Costa AC. 2005. Down syndrome and genetics - a case of linked histories. Nat Rev Genet 6: 137–147.

Periculou A, Ventura D, Rao N, Abramowitz W. 2006. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 79: 134–143.

Reeves RH, Irving NG, Moran TH, Wohin A, Kott C, Sisodia SS, Schmidt C, Bronson RT, Davison MT. 1995. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11: 177–184.

Roberson R, Toslo L, Abebe D, Spong CY. 2006. Altered expression of KIF17, a kinesin motor protein associated with NR2B trafficking, may mediate learning deficits in a Down syndrome mouse model. Am J Obstet Gynecol 198: 313.e1–313.e4.

Rueda N, Llorens-Martín M, Florez J, Valdivian E, Banerjee P, Trejo JL, Martinez-Cue C. 2010. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimer Dis 21: 277–290.

Selig D, Hjelmstad G0, Herron C, Nicoll RA, Malenka RC. 1995. Independent mechanisms for long-term depression of AMPA and NMDA responses. Neuron 15: 417–426.

Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z. 1999. Increased synaptic depression in the Ts65Dn mouse, a model for Down syndrome. Behav Brain Res 121: 610–622.

Malenka RC, Bear MF. 2004. LTD and LTP: An embarrassment of riches. Neuron 44: 5–21.

Miyawaki T, Uchida CC, Blank M, Feng DD, Burlingame AL, Garner CC. 2009. Normal protein composition of synapses in Ts65Dn mice: A mouse model of Down syndrome. J Neurochem 110: 157–169.

Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holdent JF, Fenwick RG Jr, Warren ST, et al. 1991. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 368: 235–239.

Liu C, Belichenko PV, Zhang L, Fu D, Kleschevnikov AM, Baldini A, Lejeune J. 1959. Le mongolism: Premier exemple d'aberration autosomique humaine. Ann Genet 1: 1–49.

Kornhuber J, Quack G. 1995. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137–139.

Lejeune J. 1959. Le mongolism: Premier exemple d’aberration autosomique humaine. Ann Genet 1: 1–49.

Lieberman DN, Mody I. 1994. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 368: 235–239.

Liu C, Belichenko PV, Zhang L, Fu D, Kleschevnikov AM, Baldini A, Antonarakis SE, Mobley WC, Yu YE. 2011. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Proc Natl Acad Sci 108: 1047–1058.

Received September 9, 2011; accepted in revised form October 12, 2011.
Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine

Jonah J. Scott-McKean and Alberto C.S. Costa

Learn. Mem. 2011, 18:
Access the most recent version at doi:10.1101/lm.024182.111

Supplemental Material
http://learnmem.cshlp.org/content/suppl/2011/11/18/18.12.774.DC1

References
This article cites 39 articles, 4 of which can be accessed free at:
http://learnmem.cshlp.org/content/18/12/774.full.html#ref-list-1

License

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.

© 2011 Cold Spring Harbor Laboratory Press